静脉美洛昔康与酮咯酸用于全关节置换术后疼痛控制的随机双盲对照试验
这项双盲随机对照试验纳入223例全关节置换患者,比较静脉美洛昔康与静脉酮咯酸对疼痛评分、阿片类药物用量和住院时间的影响。结果显示美洛昔康组术后24小时阿片类药物总用量增加、住院时间延长,但两组疼痛评分和恶心无差异。
要点
- 美洛昔康组术后24小时阿片类药物总用量高于酮咯酸组。
- 美洛昔康组住院时间长于酮咯酸组,当日出院率低于酮咯酸组。
- 两组疼痛评分和恶心无差异。
核心结论
- 静脉美洛昔康作为围手术期疼痛管理方案的一部分,导致阿片类药物用量增加、住院时间延长、当日出院率低于静脉酮咯酸。
研究设计与样本
- 双盲随机对照试验,共223例患者被随机分组,美洛昔康组术前两小时予30 mg静脉美洛昔康,酮咯酸组术中予15 mg静脉酮咯酸后每六小时15 mg静脉给药、计划两剂。
- 研究在clinicaltrials.gov注册(NCT05291598)并获得机构审查委员会批准,其他机构方案和药物保持不变。
- 先验效能分析显示共需170例患者。
主要发现
- 美洛昔康组术后24小时阿片类药物总用量高于酮咯酸组。
- 美洛昔康组住院时间长于酮咯酸组。
- 两组疼痛评分无差异,两组恶心无差异。
关键数值与推荐
- 美洛昔康组术后24小时阿片类药物总用量增加、住院时间延长,疼痛评分和恶心无差异。
- 美洛昔康组当日出院率低于酮咯酸组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although joint arthroplasty surgery is considered safe and effective in reducing osteoarthritis-related pain long-term, the surgery is known to be painful in the immediate postoperative period. Therefore, optimal pain management has become a crucial goal for orthopedic surgeons. Nonsteroidal anti-inflammatory drugs are often used but can cause adverse effects due to their mechanism of action. Meloxicam, however, has a unique mechanism of action, allowing it to better spare the gut lining, translating to reduced complications. This double-blind randomized controlled trial sought to compare intravenous (IV) meloxicam and IV ketorolac for total joint arthroplasty regarding pain scores, opioid consumption, and lengths of stay. METHODS: All other institutional protocols and medications remained unchanged. A total of 223 patients were randomized. The meloxicam group received 30 mg IV meloxicam preoperatively two hours before primary incision, while the ketorolac group received 15 mg IV ketorolac intraoperatively followed by 15 mg IV every six hours, scheduled for two doses. Pain, opioid consumption, and nausea were recorded at two and 24 hours postoperatively. An a priori power analysis demonstrated a need for 170 total patients. The study was registered on clinicaltrials.gov (NCT05291598) and received Institutional Review Board approval. RESULTS: The IV meloxicam group had increased total opioid consumption 24 hours postoperatively and longer lengths of stay than the IV ketorolac group; however, there were no differences in pain scores or nausea. CONCLUSIONS: The use of IV meloxicam as part of a perioperative pain management protocol led to increased opioid consumption, longer lengths of stay, and a lower rate of same-day discharges than IV ketorolac.
引用
- Rizzo MG, Costello JP, Constantinescu DS, et al. Intravenous Meloxicam Versus Ketorolac for Pain Control Following Total Joint Arthroplasty: A Double-Blind Randomized Controlled Trial. J Arthroplasty. 2025. PMID: 41167538. doi:10.1016/j.arth.2025.10.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。